Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab a potential tool in cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab a potential tool in cancer research [1]. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tifcemalimab inhibitor inhibit